Dossier - 24/05/2012 Biochips microsystems technology for the life sciences Nanoscale robots and intelligent measurement systems in arteries, fingernail-sized DNA chips that can be used to analyze thousands of genes in tiny samples, intelligent DNA microsensors – the trend in the life sciences is moving towards miniaturization. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biochips-microsystems-technology-for-the-life-sciences
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
Press release - 18/11/2022 Leading Swiss laboratory equipment manufacturer Hamilton Bonaduz AG buys Freiburg-based microfluidic technology company BioFluidix GmbH BioFluidix GmbH, a spin-off resulting from the cooperation between Hahn-Schickard and the Department of Microsystems Engineering at the University of Freiburg, is now part of the Swiss Hamilton Bonaduz AG.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fuehrender-laborgeraetehersteller-hamilton-bonaduz-ag-kauft-freiburger-mikrodosierunternehmen-biofluidix-gmbh
Article - 26/07/2019 New test assay leads to discovery of new influenza virus infection route Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…https://www.gesundheitsindustrie-bw.de/en/article/news/alternativer-infektionsweg-fuer-grippeviren-durch-neues-testverfahren-entdeckt
Biochip systems - 02/09/2020 Miniature organs with great potential Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
Microfluidic systems - 18/11/2021 Dermagnostix develops molecular diagnostic tests for skin diseases Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023. The start-up is already working on two other dermatological tests. Centrifugal microfluidics is the name of the technology on which the tests are based.https://www.gesundheitsindustrie-bw.de/en/article/news/dermagnostix-develops-molecular-diagnostic-tests-skin-diseases
Press release - 22/02/2022 Better understanding communication between neurons in the brain In the field of optogenetics, scientists investigate the activity of neurons in the brain using light. A team led by Prof. Dr. Ilka Diester and Dr. David Eriksson from the Optophysiology Laboratory at the University of Freiburg has developed a new method to simultaneously conduct laminar recordings, multifiber stimulations, 3D optogenetic stimulation, connectivity inference, and behavioral quantification on brains.https://www.gesundheitsindustrie-bw.de/en/article/press-release/better-understanding-communication-between-neurons-brain
Press release - 02/06/2022 Groundbreaking ceremony for new research building on the Faculty of Engineering campus Dr. Nicole Hoffmeister-Kraut, Minister of Economic Affairs, Labour and Tourism of Baden-Württemberg, together with Freiburg’s Mayor Martin Horn, gives the go-ahead for the construction project on the Georges-Köhler-Allee.https://www.gesundheitsindustrie-bw.de/en/article/press-release/groundbreaking-ceremony-new-research-building-faculty-engineering-campus
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
Article - 10/03/2021 Faster to single cells using miniature grinder Tissue cells are needed for medical diagnostics, cell therapies and tissue engineering, among other things. A novel tissue grinder gently and automatically dissociates cells from tissue. In November 2020, the newly founded biotech company Fast Forward Discoveries GmbH (FFX) delivered its first tissue grinders to customers.https://www.gesundheitsindustrie-bw.de/en/article/news/faster-single-cells-using-miniature-grinder
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform